Abstract
The biological effects of oxidized LDL (oxLDL) may contribute to initiation and progression of the atherosclerotic process, and the association between cardiovascular disease and oxidation of LDL has been largely demonstrated. The objectives of this study were to establish the reference values of oxidative stress biomarkers in a young healthy Spanish population to determine the concentration of oxLDL and its relationship with lipid profile and with these biomarkers. oxLDL, F2-isoprostanes, protein carbonyls (PC), and 8-hydroxy-2′-deoxyguanosine (8-OHdG) were determinate by ELISA in 72 healthy subjects. Antioxidant enzymes, superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione reductase (GR) were carried out on a Hitachi 912 analyzer; lipid profile were assayed using automated systems (Cobas 711, Roche Diagnostics). All statistics were analyzed by using SPSS for Windows 15.0. SPSS Inc, Chicago, IL, USA. (Normal mean reference values): oxLDL (63.23 ± 16.23 U/L), (Male/Female 68.06 ± 17.69/58.39 ± 13.6 U/L), F2-isoprostanes (2.26 ± 0.9 μg/g creatinine), PC (0.34 ± 0.15 nmol/mg), 8-OHdG (23.27 ± 10.58 ng/ml), SOD (931.97 ± 271.09 U/g Hb), GR (46.56 ± 11.68 U/L), GPx (27.58 ± 6.89 U/gHb (Male/Female 25.91 ± 5.03/29.2 ± 8.07 U/L)). OxLDL (63.23 U/L) was significantly (p < 0.05) positively correlated with BMI (22.53 Kg/m2), total cholesterol (175.79 mg/dl), triglycerides (87.58 mg/dl), LDL cholesterol (96.25 mg/dl), and uric acid (4.78 mg/dl), while negatively correlated with HDL-cholesterol (62.25 mg/dl). We have found different correlation between oxLDL and isoprostanes by gender with the rest of parameters. Normal reference values have been found significantly different for oxLDL and GPx by gender. Oxidized LDL is correlated with lipid profile but not with the oxidative stress biomarkers. Urinary isoprostanes are positively correlated with triglycerides and negatively with GR and GPx.
Similar content being viewed by others
References
Alcaraz-García MJ, Albaladejo MD, Acevedo C, Olea A, Zamora S, Martínez P, Parra S (2008) Effects of hyperoxia on biomarkers of oxidative stress in closed-circuit oxygen military divers. J Physiol Biochem 64:135–141
Calmarza Calmarza P (2008) Lipoproteínas de baja densidad (LDL) oxidadas. Electron J Biomed 3:52–60
Cerdá B, Soto C, Albaladejo MD, Martínez P, Sánchez-Gascón F, Tomás-Barberán F, Espín JC (2006) Pomegranate juice supplementation in chronic obstructive pulmonary disease: a 5-week randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr 60:245–253
Cesari M, Kritchevsky SB, Nicklas BJ, Penninx BW, Holvoet P, Koh-Banerjee P, Cummings SR, Harris TB, Newman AB, Pahor M (2005) Lipoprotein peroxidation and mobility limitation: results from the Health, Aging, and Body Composition Study. Arch Intern Med 165:2148–2154
Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE (2001) Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103:1955–1960
Fenollar M, Parra S, Albaladejo MD, Cassinello N (2005) Perfil lipídico y estado oxidativo en pacientes con Enfermedad Vascular Periférica. Anales de cirugía cardíaca y Vascular 11(3):124–128
Flores L, Rodela S, Abian J, Claria J, Esmatjes E (2004) F2 isoprostane is already increased at the onset of type 1 diabetes mellitus: effect of glycemic control. Metabolism 53:1118–1120
Galle J, Hansen-Hagge T, Wanner C, Seibold S (2006) Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis 185:219–226
Glass CK, Witztum JL (2001) Atherosclerosis. The road ahead. Cell 104:503–516
Holvoet P, Collen D (1998) Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis. Atherosclerosis 137:S33–S38
Holvoet P, Vanhaecke J, Janssens S (1998) Van de, W. F.; Collen, D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98:1487–1494
Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, Van de WF (2001) Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21:844–848
Huang JM, Huang ZX, Zhu W (1998) Mechanism of high-density lipoprotein subfractions inhibiting copper-catalyzed oxidation of low-density lipoprotein. Clin Biochem 31:537–543
Kauffman LD, Sokol RJ, Jones RH, Awad JA, Rewers MJ, Norris JM (2003) Urinary F2-isoprostanes in young healthy children at risk for type 1 diabetes mellitus. Free Radic Biol Med 35:551–557
Mackness MI, Abbott C, Arrol S, Durrington PN (1993) The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 294(Pt 3):829–834
Mackness MI, Durrington PN, Mackness B (2000) How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol 11:383–388
Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W (2005) Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 112:651–657
Metso S, Loimaala A, Mercuri MF, Nenonen A, Vuori I, Oja P, Bond MG, Laine S, Rontu R, Lehtimaki T (2004) Circulating oxidized low-density lipoprotein and common carotid artery intima-media thickness in a random sample of middle-aged men. J Biomed Sci 11:356–361
Morrow JD, Minton TA, Mukundan CR, Campbell MD, Zackert WE, Daniel VC et al (1994) Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostanes. J Biol Chem 269:4317–4326
Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman AM (2004) The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 45:993–1007
Ozata M, Mergen M, Oktenli C, Aydin A, Sanisoglu SY, Bolu E, Yilmaz MI, Sayal A, Isimer A, Ozdemir IC (2002) Increased oxidative stress and hypozincemia in male obesity. Clin Biochem 35:627–631
Parra Pallarés S, Albaladejo Otón MD, Martínez Hernández P (2000) Modificaciones cualitativas de las lipoproteínas. Implicaciones fisiopatológicas. An Med Interna (Madrid) 17:317–323
Parthasarathy S, Barnett J, Fong LG (1990) High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1044:275–283
Pincemail J, Siquet J, Chapelle JP, Cheramy-Bien JP, Paulissen G, Chantillon AM, Christiaens G, Gielen J, Limet R, Defraigne JO (2000) [Determination of plasma concentrations of antioxidants, antibodies against oxidized LDL, and homocysteine in a population sample from Liege]. Ann Biol Clin (Paris) 58:177–185
Poulsen HE, Prieme H, Loft S (1998) Role of oxidative DNA damage in cancer initiation and promotion. Eur J Cancer Prev 7:9–16
Ruano J, López-Miranda J, Marín C, Gómez P, Moreno JA, Fuentes F, Cortés B, Lozano A, Pérez-Martínez P, Pérez-Jiménez F (2005) La ingesta aguda de un desayuno basado en aceite de oliva con alto contenido en polifenoles mejora la función endotelial en el periodo postpandrial. Nutr Hosp 20:139–149, http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-16112005000300009&lng=es
Scheffer PG, Henry RM, Wever EJ, van Rooij GJ, Bos G, Heine RJ, Dekker JM, Diamant M, Stehouwer CD, Nijpels G, Blankenstein MA, Teerlink T (2004) LDL oxidative modifications in well- or moderately controlled type 2 diabetes. Diabetes/Metab Res Rev 20:298–304
Sies H (1985) Oxidative stress: introductory remarks. In: Sies H (ed) Oxidative stress. Academic, New york, pp 1–8
Sigurdardottir V, Fagerberg B, Wikstrand J, Schmidt C, Hulthe J (2008) Circulating oxidized LDL is associated with the occurrence of echolucent plaques in the carotid artery in 61-year-old men. Scand J Clin Lab Invest 68:292–297
Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, Shimamura K, Kimura J, Michishita I, Suzuki T, Nagai R (2000) Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 20:2243–2247
Tsukahara H (2007) Biomarkers for oxidative stress: clinical application in pediatric medicine. Curr Med Chem 14:339–351
Tsuzura S, Ikeda Y, Suehiro T, Ota K, Osaki F, Arii K, Kumon Y, Hashimoto K (2004) Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism 53:297–302
Van der Zwan LP, Teerlink T, Dekker JM, Henry RM, Stehouwer CD, Jakobs C, Heine RJ, Scheffer PG (2009) Circulating oxidized LDL: determinants and association with brachial flow-mediated dilation. J Lipid Res 50:342–349
Van Tits LJ, van Himbergen TM, Lemmers HL (2006) de, G. J.; Stalenhoef, A. F. Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 185:307–312
Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, Du BN, Fogelman AM, Berliner JA (1995) Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 95:774–782
Acknowledgements
The work described here has received funding from the European Community's Sixth Framework Programme under grant agreement FOOD-023115, Healthy Structuring.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Burgos Alves, M.I., Avilés Plaza, F., Martínez-Tomás, R. et al. Oxidized LDL and its correlation with lipid profile and oxidative stress biomarkers in young healthy Spanish subjects. J Physiol Biochem 66, 221–227 (2010). https://doi.org/10.1007/s13105-010-0028-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13105-010-0028-4